Logos Capital, Lilly Asia Ventures and Lyfe Capital, the biotech’s executives explained to Fierce that it was a combination of previous relationships with some of these investors and excitement ...

and Logos Capital, as new investors, with all of Adcendo's existing backers also chipping in. Meanwhile, in other recent biotech financing news, Enveda raised $130 million in a Series C round that ...

Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech ... Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital ...